Page last updated: 2024-10-21

phenytoin and Cerebral Ischemia

phenytoin has been researched along with Cerebral Ischemia in 38 studies

Research Excerpts

ExcerptRelevanceReference
"Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable."7.80Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014)
"Topiramate, a structurally novel anticonvulsant, and phenytoin were evaluated in a rat model of ischemia-induced epilepsy."7.69Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. ( Edmonds, HL; Jiang, YD; Shank, RP; Zhang, PY, 1996)
" The present experiments compared the noncompetitive N-methyl-D-aspartate antagonists phencyclidine and MK-801 with the anticonvulsant phenytoin in a model of focal brain ischemia."7.68Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. ( Boxer, PA; Cordon, JJ; Mann, ME; Marcoux, FW; Rock, DM; Rodolosi, LC; Taylor, CP; Vartanian, MG, 1990)
" The purpose of the present experiment is to study the therapeutic effect of phenytoin on cerebral ischemia and confirm whether the effectiveness of phenytoin could be enhanced by combination of free radical scavengers such as mannitol and vitamin E."7.67[Protective effect of phenytoin and its enhanced action by combined administration of mannitol and vitamin E in cerebral ischemia]. ( Abiko, H; Mizoi, K; Oba, M; Suzuki, J; Yoshimoto, T, 1986)
"To study the protective effect of phenytoin on postischemic brain damage, total cerebral ischemia was produced for 8-12 min (aortic occlusion balloon catheter method) in 36 adult mongrel dogs."7.66Effects of phenytoin on regional cerebral blood flow, electroencephalogram, and electrolyte contents in cerebral blood and cerebral cortex following total cerebral ischemia in dogs. ( Fukuda, A; Ihara, N; Ikeda, H; Kohama, A; Tabuse, H; Tanabe, J, 1983)
"Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable."3.80Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014)
"Na(+)K(+)-ATPase activity, water content, and Na+/K+ concentrations in the parietal cortex were measured in untreated and phenytoin-treated rats following global cerebral ischemia."3.69Effect of phenytoin on cortical Na(+)-K(+)-ATPase activity in global ischemic rat brain. ( Imaizumi, S; Kinouchi, H; Kurosawa, K; Yoshimoto, T, 1995)
"Topiramate, a structurally novel anticonvulsant, and phenytoin were evaluated in a rat model of ischemia-induced epilepsy."3.69Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. ( Edmonds, HL; Jiang, YD; Shank, RP; Zhang, PY, 1996)
" The present experiments compared the noncompetitive N-methyl-D-aspartate antagonists phencyclidine and MK-801 with the anticonvulsant phenytoin in a model of focal brain ischemia."3.68Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. ( Boxer, PA; Cordon, JJ; Mann, ME; Marcoux, FW; Rock, DM; Rodolosi, LC; Taylor, CP; Vartanian, MG, 1990)
" The purpose of the present experiment is to study the therapeutic effect of phenytoin on cerebral ischemia and confirm whether the effectiveness of phenytoin could be enhanced by combination of free radical scavengers such as mannitol and vitamin E."3.67[Protective effect of phenytoin and its enhanced action by combined administration of mannitol and vitamin E in cerebral ischemia]. ( Abiko, H; Mizoi, K; Oba, M; Suzuki, J; Yoshimoto, T, 1986)
"To study the protective effect of phenytoin on postischemic brain damage, total cerebral ischemia was produced for 8-12 min (aortic occlusion balloon catheter method) in 36 adult mongrel dogs."3.66Effects of phenytoin on regional cerebral blood flow, electroencephalogram, and electrolyte contents in cerebral blood and cerebral cortex following total cerebral ischemia in dogs. ( Fukuda, A; Ihara, N; Ikeda, H; Kohama, A; Tabuse, H; Tanabe, J, 1983)
"When phenytoin was discontinued, valproate levels increased, and he progressively improved."1.30Exceptionally long absence status: multifactorial etiology, drug interactions and complications. ( Andermann, F; Bastos, A; D'Agostino, MD; Dubeau, F; Fedi, M, 1999)
"In complete global ischemia (cardiac arrest) reperfusion is characterized by an immediate reactive hyperemia followed within 20-30 min by a delayed hypoperfusion state."1.29[Cerebral protection]. ( Cattaneo, AD, 1993)
"When phenytoin was administered immediately after the hypoxia, there was no difference between vehicle-injected controls and phenytoin-treated pups."1.29Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats. ( Hamada, Y; Hattori, H; Hayakawa, T; Maihara, T; Mikawa, H, 1994)
"The duration of the vegetative state was 12 days, 15 days or about 4 months until death and was associated with corresponding stages of generalized ischemic brain damage."1.29Relationship between ischemic damage and concentrations of phenytoin and phenobarbital in the brain cortex of epileptic patients in vegetative state at death. ( Jürgens, U; Lahl, R; May, T; Rambeck, B; Schnabel, R, 1996)
"With regard to the degree of brain swelling, a similar dose-related suppressive effect was seen in the phenytoin-treated groups."1.27Protective effect of phenytoin and its enhanced action by combined administration with mannitol and vitamin E in cerebral ischaemia. ( Abiko, H; Mizoi, K; Oba, M; Suzuki, J; Yoshimoto, T, 1987)
"Mannitol treatment had no protective effect, but phenytoin, vitamin E and dexamethasone had clear dose-dependent effect."1.27[Protective effect of various agents against ischemic neuronal damage in guinea pig hippocampal neurons studied in vitro]. ( Amagasa, M; Mizoi, K; Suzuki, J; Yoshimoto, T, 1988)

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-199014 (36.84)18.7374
1990's19 (50.00)18.2507
2000's2 (5.26)29.6817
2010's3 (7.89)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sathishkumar, D1
George, R1
Irodi, A1
Thomas, M1
Karamchandani, RR1
Fletcher, JJ1
Pandey, AS1
Rajajee, V1
Maconochie, I1
Ross, M1
Tanabe, M1
Umeda, M1
Honda, M1
Ono, H1
Fukuda, A1
Tabuse, H1
Ihara, N1
Tanabe, J1
Ikeda, H1
Kohama, A1
Bremer, AM1
Yamada, K1
West, CR1
Shiu, GK1
Nemoto, EM2
Nemmer, J1
Aldrete, JA2
Artru, AA1
Michenfelder, JD2
Taylor, CP4
Burke, SP1
Weber, ML2
Watson, GB1
Lanthorn, TH1
Imaizumi, S2
Kurosawa, K1
Kinouchi, H2
Yoshimoto, T7
Rataud, J1
Debarnot, F1
Mary, V1
Pratt, J1
Stutzmann, JM1
Cattaneo, AD1
Hayakawa, T1
Hamada, Y1
Maihara, T1
Hattori, H1
Mikawa, H1
Edmonds, HL1
Jiang, YD1
Zhang, PY1
Shank, RP1
Vartanian, MG2
Cordon, JJ2
Kupina, NC1
Schielke, GP1
Posner, A1
Raser, KJ1
Wang, KK1
Schnabel, R1
Rambeck, B1
May, T1
Jürgens, U1
Lahl, R1
Iwasaki, H1
Ohmachi, Y1
Takashima, K1
Tani, S1
Kasuya, H1
Shimizu, T1
Frantseva, MV1
Carlen, PL1
El-Beheiry, H1
Saito, Y1
Hashimoto, T1
Iwata, H1
Takahashi, K1
Fukumizu, M1
Sasaki, M1
Hanaoka, S1
Sugai, K1
D'Agostino, MD1
Andermann, F1
Dubeau, F1
Fedi, M1
Bastos, A1
Behringer, W1
Kentner, R1
Wu, X1
Tisherman, SA1
Radovsky, A1
Stezoski, WS1
Henchir, J1
Prueckner, S1
Safar, P1
Romo-Salas, F1
Jankovsky, L1
Franatovic, Y1
Qi, L1
Dong, W1
Mizoi, K5
Boxer, PA1
Mann, ME1
Rodolosi, LC1
Rock, DM1
Marcoux, FW1
Motomiya, M1
Amagasa, M2
Ogawa, A1
Magalini, SI1
Sabato, AF1
Pala, F1
Abiko, H2
Suzuki, J3
Oba, M2
Aitkenhead, A1
Heuser, D1
Guggenberger, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964]550 participants (Actual)Interventional2009-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.27
Placebo-0.89

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.57
Placebo0.16

Change in Cognitive Function From Baseline

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery

Interventionunits on a scale (Mean)
Lidocaine0.09
Placebo0.07

Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

Interventionunits on a scale (Mean)
Lidocaine0.07
Placebo0.07

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine6.3
Placebo6.96

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-10.98
Placebo-11.67

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.07

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.04

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.02
Placebo-0.02

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.04
Placebo-0.01

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.71
Placebo-1.16

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine1.23
Placebo-0.49

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.20
Placebo0.03

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.95
Placebo1.59

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-6.70
Placebo-6.39

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-7.12
Placebo-6.31

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.39
Placebo-1.48

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-0.67
Placebo-0.8

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.46
Placebo-1.02

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-3
Placebo-3.21

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.15
Placebo-0.31

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine2.46
Placebo2.1

Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

InterventionParticipants (Count of Participants)
Lidocaine87
Placebo83

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year

,
Interventionunits on a scale (Mean)
1 year Change Work Activities1 year Change General health perception
Lidocaine-1.37-0.28
Placebo-1.42-0.43

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks

,
Interventionunits on a scale (Mean)
6-Week Change Work activities6-Week Change General health perception
Lidocaine2.71-0.004
Placebo3-0.03

Transcerebral Activation Gradient of Platelet-neutrophil Conjugates

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.150.02-0.73-0.10
Placebo-0.43-0.73-0.400.19

Transcerebral Activation Gradients of Monocytes

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-4.22-2.46-0.341.21
Placebo-0.041.832.640.54

Transcerebral Activation Gradients of Neutrophils

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-2.020.560.581.04
Placebo-0.080.171.19-0.68

Transcerebral Activation Gradients of Platelets

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.030.030.330.37
Placebo0.350.430.050.27

Reviews

5 reviews available for phenytoin and Cerebral Ischemia

ArticleYear
Head injury (moderate to severe).
    BMJ clinical evidence, 2010, Jun-10, Volume: 2010

    Topics: Acute Disease; Anticonvulsants; Brain Injuries; Brain Ischemia; Coma; Craniocerebral Trauma; Glasgow

2010
Apneustic breathing in children with brainstem damage due to hypoxic-ischemic encephalopathy.
    Developmental medicine and child neurology, 1999, Volume: 41, Issue:8

    Topics: Brain; Brain Diseases; Brain Ischemia; Brain Stem; Child, Preschool; Dose-Response Relationship, Dru

1999
[Cerebral protection].
    Recenti progressi in medicina, 1986, Volume: 77, Issue:1

    Topics: Animals; Barbiturates; Brain Ischemia; Diuretics; Fatty Acids, Nonesterified; Humans; Hypothermia, I

1986
Ionic changes in brain ischaemia and alterations produced by drugs.
    British journal of anaesthesia, 1985, Volume: 57, Issue:1

    Topics: Animals; Biological Transport, Active; Brain Ischemia; Calcium; Calcium Channel Blockers; Cats; Extr

1985
Cerebral preservation for intraoperative focal ischemia.
    Clinical neurosurgery, 1985, Volume: 32

    Topics: Adenosine Triphosphate; Anesthesia; Anesthetics; Aneurysm; Animals; Barbiturates; Brain; Brain Disea

1985

Other Studies

33 other studies available for phenytoin and Cerebral Ischemia

ArticleYear
PHACES syndrome with moyamoya vasculopathy - a case report.
    Dermatology online journal, 2013, Aug-15, Volume: 19, Issue:8

    Topics: Anticonvulsants; Aortic Coarctation; Aspirin; Brain Ischemia; Child, Preschool; Eye Abnormalities; F

2013
Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2014, Volume: 21, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Brain Ischemia; Female; Follow-Up Stud

2014
Phenytoin and carbamazepine delay the initial depression of the population spike upon exposure to in vitro ischemia and promote its post-ischemic functional recovery in rat hippocampal slices.
    European journal of pharmacology, 2006, Dec-28, Volume: 553, Issue:1-3

    Topics: Animals; Anticonvulsants; Brain Ischemia; Carbamazepine; Electrophysiology; Glucose; Hippocampus; Hy

2006
Effects of phenytoin on regional cerebral blood flow, electroencephalogram, and electrolyte contents in cerebral blood and cerebral cortex following total cerebral ischemia in dogs.
    Circulatory shock, 1983, Volume: 10, Issue:4

    Topics: Animals; Brain Ischemia; Cerebral Cortex; Cerebrovascular Circulation; Dogs; Electroencephalography;

1983
Ischemic cerebral edema in primates: effects of acetazolamide, phenytoin, sorbitol, dexamethasone, and methylprednisolone on brain water and electrolytes.
    Neurosurgery, 1980, Volume: 6, Issue:2

    Topics: Acetazolamide; Animals; Brain; Brain Edema; Brain Ischemia; Cerebral Cortex; Dexamethasone; Haplorhi

1980
Dose of thiopental, pentobarbital, and phenytoin for maximal therapeutic effects in cerebral ischemic anoxia.
    Critical care medicine, 1983, Volume: 11, Issue:6

    Topics: Animals; Brain Chemistry; Brain Ischemia; Fatty Acids, Nonesterified; Female; Hypoxia, Brain; Ketami

1983
Phenytoin in the treatment of cerebral ischemia.
    Anesthesia and analgesia, 1981, Volume: 60, Issue:8

    Topics: Animals; Blood Pressure; Brain Ischemia; Cerebrovascular Circulation; Humans; Phenytoin; Rabbits

1981
Phenytoin in the treatment of cerebral ischemia.
    Anesthesia and analgesia, 1981, Volume: 60, Issue:8

    Topics: Animals; Blood Pressure; Brain Ischemia; Cardiac Output; Cerebrovascular Circulation; Dogs; Phenytoi

1981
Hippocampal slices: glutamate overflow and cellular damage from ischemia are reduced by sodium-channel blockade.
    Journal of neuroscience methods, 1995, Volume: 59, Issue:1

    Topics: Animals; Brain Ischemia; Electrophysiology; Glutamic Acid; Hippocampus; In Vitro Techniques; Phenyto

1995
Phenytoin delays ischemic depolarization, but cannot block its long-term consequences, in the rat hippocampal slice.
    Neuropharmacology, 1995, Volume: 34, Issue:5

    Topics: Animals; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Hippocam

1995
Effect of phenytoin on cortical Na(+)-K(+)-ATPase activity in global ischemic rat brain.
    Journal of neurotrauma, 1995, Volume: 12, Issue:2

    Topics: Animals; Body Water; Brain Ischemia; Cerebral Cortex; Male; Phenytoin; Potassium; Rats; Rats, Wistar

1995
Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials.
    Brain research, 1994, Nov-21, Volume: 664, Issue:1-2

    Topics: Action Potentials; Animals; Brain Ischemia; Evoked Potentials; Hippocampus; Hypoxia, Brain; In Vitro

1994
Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents.
    Neuroscience letters, 1994, May-19, Volume: 172, Issue:1-2

    Topics: Animals; Anticonvulsants; Brain Ischemia; Carbamazepine; Cerebral Arteries; Electrophysiology; Elect

1994
[Cerebral protection].
    Minerva anestesiologica, 1993, Volume: 59, Issue:9

    Topics: Adrenal Cortex Hormones; Anesthetics; Barbiturates; Benzodiazepines; Brain Ischemia; Calcium Channel

1993
Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats.
    Life sciences, 1994, Volume: 54, Issue:6

    Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Corpus Stria

1994
Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy.
    Life sciences, 1996, Volume: 59, Issue:10

    Topics: Acoustic Stimulation; Animals; Anticonvulsants; Brain Ischemia; Epilepsy; Fructose; Male; Phenytoin;

1996
Phenytoin pretreatment prevents hypoxic-ischemic brain damage in neonatal rats.
    Brain research. Developmental brain research, 1996, Sep-02, Volume: 95, Issue:2

    Topics: Animals; Animals, Newborn; Anticonvulsants; Body Temperature Regulation; Brain Damage, Chronic; Brai

1996
Relationship between ischemic damage and concentrations of phenytoin and phenobarbital in the brain cortex of epileptic patients in vegetative state at death.
    Epilepsy research, 1996, Volume: 25, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Autopsy; Brain Ischemia; Case-Control Studies; Cere

1996
Optimal dose for barbiturate protection of the ischemic brain.
    Anesthesiology, 1996, Volume: 85, Issue:6

    Topics: Animals; Anticonvulsants; Barbiturates; Brain Ischemia; Dose-Response Relationship, Drug; Humans; Ph

1996
Phenytoin-induced cerebral thrombosis in rats: cerebral ultrastructure, water content and ischaemic volume in the acute phase.
    International journal of experimental pathology, 1996, Volume: 77, Issue:5

    Topics: Acute Disease; Animals; Arteries; Brain Edema; Brain Ischemia; Cerebral Cortex; Disease Models, Anim

1996
A submersion method to induce hypoxic damage in organotypic hippocampal cultures.
    Journal of neuroscience methods, 1999, Jul-01, Volume: 89, Issue:1

    Topics: Animals; Brain Ischemia; Cell Death; Cell Hypoxia; Culture Media; Electric Stimulation; Hippocampus;

1999
Exceptionally long absence status: multifactorial etiology, drug interactions and complications.
    Epileptic disorders : international epilepsy journal with videotape, 1999, Volume: 1, Issue:4

    Topics: Aged; Anticonvulsants; Brain Ischemia; Dementia, Vascular; Drug Interactions; Epilepsy, Generalized;

1999
Thiopental and phenytoin by aortic arch flush for cerebral preservation during exsanguination cardiac arrest of 20 minutes in dogs. An exploratory study.
    Resuscitation, 2001, Volume: 49, Issue:1

    Topics: Animals; Anticonvulsants; Aorta, Thoracic; Brain Ischemia; Cardiopulmonary Resuscitation; Cerebrovas

2001
Effect of pretreatment with thiopental and phenytoin on postischemic brain damage in rabbits.
    Critical care medicine, 1979, Volume: 7, Issue:10

    Topics: Animals; Brain Ischemia; Hypoxia, Brain; Phenytoin; Placebos; Rabbits; Thiopental

1979
[Protective action of phenytoin on cerebral ischemia in rats].
    Zhonghua yi xue za zhi, 1992, Volume: 72, Issue:7

    Topics: Animals; Brain Ischemia; Calcium-Transporting ATPases; Electroencephalography; Female; Male; Phenyto

1992
Intraoperative monitoring of the somatosensory evoked potentials and cerebral blood flow during aneurysm surgery--safety evaluation for temporary vascular occlusion.
    Neurologia medico-chirurgica, 1991, Volume: 31, Issue:6

    Topics: Brain Ischemia; Cerebrovascular Circulation; Drug Combinations; Evoked Potentials, Somatosensory; Hu

1991
Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat.
    Stroke, 1990, Volume: 21, Issue:11 Suppl

    Topics: Animals; Brain Ischemia; Disease Models, Animal; Dizocilpine Maleate; Male; N-Methylaspartate; Phenc

1990
Phenytoin affects metabolism of free fatty acids and nucleotides in rat cerebral ischemia.
    Stroke, 1990, Volume: 21, Issue:9

    Topics: Animals; Brain Ischemia; Cytidine Triphosphate; Energy Metabolism; Fatty Acids, Nonesterified; Male;

1990
Actions of brain-protecting substances against both oxygen and glucose deprivation in the guinea pig hippocampal neurons studied in vitro.
    Brain research, 1989, Dec-11, Volume: 504, Issue:1

    Topics: Action Potentials; Animals; Brain Ischemia; Electric Stimulation; Glucose; Guinea Pigs; Hippocampus;

1989
[Protective effect of phenytoin and its enhanced action by combined administration of mannitol and vitamin E in cerebral ischemia].
    No to shinkei = Brain and nerve, 1986, Volume: 38, Issue:4

    Topics: Animals; Brain Edema; Brain Ischemia; Dogs; Drug Synergism; Electroencephalography; Injections, Intr

1986
Protective effect of phenytoin and its enhanced action by combined administration with mannitol and vitamin E in cerebral ischaemia.
    Acta neurochirurgica, 1987, Volume: 88, Issue:1-2

    Topics: Animals; Brain Edema; Brain Ischemia; Dogs; Drug Therapy, Combination; Electroencephalography; Evans

1987
[Protective effect of various agents against ischemic neuronal damage in guinea pig hippocampal neurons studied in vitro].
    No shinkei geka. Neurological surgery, 1988, Volume: 16, Issue:12

    Topics: Animals; Brain Ischemia; Dexamethasone; Guinea Pigs; Hippocampus; In Vitro Techniques; Mannitol; Mic

1988
Cerebral protection.
    British journal of hospital medicine, 1986, Volume: 35, Issue:5

    Topics: Adrenal Cortex Hormones; Barbiturates; Blood Glucose; Brain Edema; Brain Ischemia; Calcium Channel B

1986